Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea · Delayed Price · Currency is KRW 73,700
+2,000 (2.79%)
Last updated: Jun 16, 2026, 2:03 PM KST
KRX:185750 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,739,214 | 1,692,404 | 1,586,431 | 1,669,404 | 1,488,345 | 1,343,559 |
Other Revenue | - | - | -0 | - | - | - |
| 1,739,214 | 1,692,404 | 1,586,431 | 1,669,404 | 1,488,345 | 1,343,559 | |
Revenue Growth (YoY) | 6.97% | 6.68% | -4.97% | 12.16% | 10.78% | 3.11% |
Cost of Revenue | 1,212,250 | 1,166,026 | 1,053,820 | 1,007,203 | 945,705 | 847,741 |
Gross Profit | 526,964 | 526,378 | 532,611 | 662,202 | 542,639 | 495,818 |
Selling, General & Admin | 270,791 | 270,575 | 267,793 | 256,595 | 237,936 | 220,982 |
Research & Development | 152,473 | 154,097 | 143,914 | 140,235 | 176,325 | 163,277 |
Amortization of Goodwill & Intangibles | 3,740 | 3,835 | 3,080 | 2,169 | 1,926 | 1,794 |
Other Operating Expenses | 12,389 | 12,139 | 12,605 | 11,694 | 11,387 | 12,206 |
Operating Expenses | 444,761 | 445,810 | 433,150 | 415,602 | 432,733 | 401,060 |
Operating Income | 82,202 | 80,568 | 99,462 | 246,599 | 109,906 | 94,759 |
Interest Expense | -7,147 | -6,699 | -8,319 | -9,271 | -6,847 | -4,030 |
Interest & Investment Income | 6,951 | 7,256 | 12,691 | 6,028 | 2,333 | 759.37 |
Earnings From Equity Investments | - | - | - | 798.36 | -460.38 | -603.47 |
Currency Exchange Gain (Loss) | -1,809 | -2,095 | 2,918 | -2,356 | -2,524 | -183.41 |
Other Non Operating Income (Expenses) | 564.87 | 1,349 | -1,208 | -1,777 | 838.33 | -10,128 |
EBT Excluding Unusual Items | 80,762 | 80,378 | 105,543 | 240,021 | 103,246 | 80,573 |
Gain (Loss) on Sale of Investments | 629.27 | 747.23 | -2,764 | 1,465 | -2,223 | -98.87 |
Gain (Loss) on Sale of Assets | 402.42 | 542.27 | 154 | 111.88 | 54.05 | 119.34 |
Asset Writedown | -15.58 | -15.58 | -923.8 | - | -3,912 | - |
Pretax Income | 81,778 | 81,652 | 102,009 | 241,598 | 97,165 | 80,594 |
Income Tax Expense | 3,210 | 3,826 | -9,433 | 27,996 | 17,187 | 38,237 |
Earnings From Continuing Operations | 78,568 | 77,827 | 111,442 | 213,602 | 79,978 | 42,356 |
Minority Interest in Earnings | -20.5 | -318.2 | -2,369 | -1,081 | 975.58 | 363.91 |
Net Income | 78,547 | 77,509 | 109,073 | 212,521 | 80,953 | 42,720 |
Net Income to Common | 78,547 | 77,509 | 109,073 | 212,521 | 80,953 | 42,720 |
Net Income Growth | -17.56% | -28.94% | -48.68% | 162.52% | 89.50% | -53.38% |
Shares Outstanding (Basic) | 13 | 13 | 13 | 14 | 13 | 14 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 14 | 13 | 14 |
Shares Change (YoY) | 0.70% | 0.50% | -5.20% | 3.79% | -1.77% | -0.73% |
EPS (Basic) | 5961.24 | 5882.09 | 8234.46 | 15210.37 | 6013.65 | 3117.38 |
EPS (Diluted) | 5923.89 | 5845.54 | 8234.00 | 15210.37 | 6013.65 | 3117.38 |
EPS Growth | -17.81% | -29.01% | -45.87% | 152.93% | 92.91% | -53.03% |
Free Cash Flow | -109,004 | -73,558 | 25,815 | 276,942 | 22,836 | -35,339 |
Free Cash Flow Per Share | -8188.39 | -5525.42 | 1948.91 | 19821.04 | 1696.38 | -2578.75 |
Gross Margin | 30.30% | 31.10% | 33.57% | 39.67% | 36.46% | 36.90% |
Operating Margin | 4.73% | 4.76% | 6.27% | 14.77% | 7.38% | 7.05% |
Profit Margin | 4.52% | 4.58% | 6.88% | 12.73% | 5.44% | 3.18% |
Free Cash Flow Margin | -6.27% | -4.35% | 1.63% | 16.59% | 1.53% | -2.63% |
EBITDA | 127,377 | 125,366 | 139,234 | 283,629 | 143,504 | 122,241 |
EBITDA Margin | 7.32% | 7.41% | 8.78% | 16.99% | 9.64% | 9.10% |
D&A For EBITDA | 45,174 | 44,798 | 39,772 | 37,030 | 33,598 | 27,482 |
EBIT | 82,202 | 80,568 | 99,462 | 246,599 | 109,906 | 94,759 |
EBIT Margin | 4.73% | 4.76% | 6.27% | 14.77% | 7.38% | 7.05% |
Effective Tax Rate | 3.93% | 4.69% | - | 11.59% | 17.69% | 47.45% |
Advertising Expenses | - | 75,738 | 74,740 | 69,707 | 60,364 | 51,329 |